GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoDyn Inc (OTCPK:CYDY) » Definitions » Debt-to-Equity

CytoDyn (CytoDyn) Debt-to-Equity : -0.26 (As of Feb. 2024)


View and export this data going back to 2005. Start your Free Trial

What is CytoDyn Debt-to-Equity?

CytoDyn's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $30.31 Mil. CytoDyn's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was $0.18 Mil. CytoDyn's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $-119.38 Mil. CytoDyn's debt to equity for the quarter that ended in Feb. 2024 was -0.26.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CytoDyn's Debt-to-Equity or its related term are showing as below:

CYDY' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.82   Med: -0.57   Max: 11.71
Current: -0.26

During the past 13 years, the highest Debt-to-Equity Ratio of CytoDyn was 11.71. The lowest was -7.82. And the median was -0.57.

CYDY's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs CYDY: -0.26

CytoDyn Debt-to-Equity Historical Data

The historical data trend for CytoDyn's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoDyn Debt-to-Equity Chart

CytoDyn Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.93 -6.19 -3.02 -0.39 -0.33

CytoDyn Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 -0.33 -0.29 -0.29 -0.26

Competitive Comparison of CytoDyn's Debt-to-Equity

For the Biotechnology subindustry, CytoDyn's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CytoDyn's Debt-to-Equity falls into.



CytoDyn Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CytoDyn's Debt to Equity Ratio for the fiscal year that ended in May. 2023 is calculated as

CytoDyn's Debt to Equity Ratio for the quarter that ended in Feb. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CytoDyn  (OTCPK:CYDY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CytoDyn Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CytoDyn's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CytoDyn (CytoDyn) Business Description

Traded in Other Exchanges
Address
1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Executives
Tyler Blok officer: EVP of Legal Affairs 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Stephen M Simes director
Ryan Dunlap director 310 N. STATE STREET, SUITE 208, LAKE OSWEGO OR 97034
Arvin Cyrus Arman officer: President 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Karen J Brunke director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Tanya Durkee Urbach director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Lishomwa C Ndhlovu director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Harish Seethamraju director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Gordon A Gardiner director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Samir Rashmikant Patel director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Antonio Migliarese officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Chris P Recknor officer: Chief Operating Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Michael D. Mulholland officer: CFO, Treasurer and Secretary 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Jordan G Naydenov director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660

CytoDyn (CytoDyn) Headlines

From GuruFocus

CytoDyn Announces President Takes Medical Leave of Absence

By sperokesalga sperokesalga 05-24-2023

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

By PurpleRose PurpleRose 07-12-2022